Form 4: Whitehawk Therapeutics Director Richard Maroun Granted 40,006 Stock Options

Whitehawk Therapeutics, Inc. Director and 10% Owner Richard E. Maroun was granted 40,006 stock options with an exercise price of $2.04, vesting over one year or prior to the next annual meeting.

Summary

• Richard E. Maroun, a Director and 10% Owner of Whitehawk Therapeutics, Inc. (WHWK), was granted 40,006 stock options.
• The stock options have an exercise price of $2.04 per share.
• The grant date for these options was June 12, 2025.
• The options are set to expire on June 12, 2035.
• The options will vest 100% on the earlier of the one-year anniversary of the grant date (June 12, 2026) or the day immediately prior to the next annual meeting of stockholders following the grant date, contingent on Mr. Maroun continuing to be a Service Provider.
• The filing also includes an Exhibit 24, a Power of Attorney dated April 25, 2025, authorizing specific individuals to file SEC reports on behalf of Richard Maroun.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While option grants can lead to dilution, they also align insider interests with shareholders. This is a standard compensation event, not indicative of major positive or negative news.

Positives

• The grant of stock options aligns the interests of Director Richard E. Maroun with those of the shareholders, as the options gain value only if the company's stock price increases.

Negatives

• The issuance of new stock options could lead to potential future dilution for existing shareholders if and when these options are exercised.

Risks

• Potential future dilution of existing shares if the 40,006 stock options are exercised.
• The vesting of the options is contingent on Richard E. Maroun continuing to be a 'Service Provider' to Whitehawk Therapeutics, Inc., meaning the benefit is tied to his ongoing association with the company.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of an insider equity grant, common across all industries as a form of executive and director compensation. It does not provide specific industry-related insights beyond the company's name, Whitehawk Therapeutics, Inc., suggesting a focus on the therapeutics or biotechnology sector.

Corporate Governance

Related Party Transactions

• The grant of stock options to a director is considered a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also increased alignment of the director's interests with shareholder value creation.
• Employees: The option grant is part of an Equity Incentive Plan, which generally benefits service providers.

Next Steps

• The stock options will vest on the earlier of June 12, 2026, or the day prior to the next annual meeting of stockholders, contingent on Mr. Maroun's continued service.

Key Dates

Keywords

Whitehawk Therapeutics, WHWK, Richard Maroun, Stock Options, SEC Form 4, Insider Transaction, Equity Incentive Plan, Director Compensation, Corporate Governance